Emerging therapeutic strategies for asthma management.
The describe the mechanisms of action of and clinical experience to date with novel asthma drug therapies. This article is based, in part, on a presentation given by Eli O. Meltzer, MD, at a symposium entitled. New Frontiers in Asthma Management: Biotechnology for Optimal Therapeutic and Economic Outcomes. at the Academy of Managed Care Pharmacy's 15th Annual Meeting and Showcase in Minneapolis, Minnesota, on April 10, 2003. Various elements of the pathophysiologic processes involved in allergic asthma, including type 2 helper T lymphocytes, cytokines, and immunoglobulin E (IgE), have been the targets of new drug research. Clinical experience with omalizumab, a humanized anti-IgE monoclonal antibody, is promising.